AI model matches radiologists in detecting clinically significant prostate cancer on MRI

Moon­Lake Im­munother­a­peu­tics’ nanobody can­di­date tri­umphed in a mid-stage pso­ri­at­ic arthri­tis tri­al fol­low­ing past suc­cess­es in hidradeni­tis sup­pu­ra­ti­va and pso­ri­a­sis, but its shares plunged amid high­er-than-ex­pect­ed

Mer­ck and Kelun-Biotech re­vealed Phase 3 breast can­cer da­ta for the lead an­ti­body-drug con­ju­gate in their po­ten­tial­ly $12 bil­lion part­ner­ship. In a Phase 3 tri­al